• Our published data showed that in mouse heart the protein

  2024-01-19

  

  Our published data showed that, in mouse heart, the protein level of WDR1 was highest during the embryonic stage, but became progressively decreased to a constant level from birth to adulthood (Yuan et al., 2014), indicating an important role of WDR1 in embryonic heart development. However, function

• Most studies on d penicillamine induced MG were performed

  2024-01-19

  

  Most studies on d-penicillamine-induced MG were performed before the discovery that some MG patients have anti-MuSK antibodies. After the identification of the present case, we retrospectively tested the stored frozen sera of ten earlier identified d-penicillamine MG patients with anti-AChR MK2 Inhi

• The following are the supplementary data related to this art

  2024-01-19

  

  The following are the supplementary data related to this article. Conflict of interest Acknowledgements Disclosure of interest Introduction Since the introduction of platinum-based chemotherapy, metastatic testicular cancer has become a curable disease and most testicular cancer patient

• To date more than different mutations in

  2024-01-19

  

  To date, more than 50 different mutations in the gene have been described (Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff: SRD5A2 Gene: http://www.hgmd.cf.ac.uk). Most of them are missense mutations but premature stop codons and deletions leading to non-functional or s

• OSMI-1 br Introduction Arginase deficiency is

  2024-01-19

  

  Introduction Arginase deficiency is a rare metabolic disorder resulting from a loss of arginase 1 (ARG1), the final enzyme in the urea cycle, which is the major pathway for the detoxification of ammonia in terrestrial mammals. ARG1 is expressed most prevalently in hepatocytes and red blood cells.

• 91 5 br Results br Discussion Evaluation of antimicrobial us

  2024-01-18

  

  Results Discussion Evaluation of antimicrobial usage is standardized using the DDD as a recommended strategy for comparison with similar hospitals [13]. The use of risk adjustment is needed to overcome the challenge of benchmarking. Two patient characteristics are associated with clinical outc

• Thalidomide is now a well known

  2024-01-18

  

  Thalidomide is now a well known antiangiogenic agent. This property of thalidomide is being extensively researched upon, for its significant utility in the treatment of various malignant tumors. Studies show that thalidomide efficaciously inhibits various pro-angiogenic factors such as tumor necrosi

• br Other Strategies for HIF

  2024-01-18

  

  Other Strategies for HIF-α Inhibition NSC-644221 is another HIF-α inhibitor acting at the translational level, independently of proteasomal degradation and VHL status, and is devoid of DNA damage-inducing properties [70]. NSC-644221 arrests Pregnenolone Carbonitrile in G2–M through a cell type-sp

• Long term blood pressure regulation

  2024-01-18

  

  Long term blood pressure regulation is linked to renal function through the mechanisms of pressure natriuresis (Evans et al., 2005), which has been shown to be modulated by the RAS (Hall et al., 1999). Key components of the RAS are expressed throughout the kidney, and are implicated in renal excreto

• br Introduction Nonalcoholic fatty liver disease NAFLD

  2024-01-18

  

  Introduction Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic spectrum of liver pathologies associated with excessive accumulation of fat in the liver. This spectrum is continuous but can be graded based on pathological features; in increasing severity, these are: bland steatosis,

• An issue related to research without biomarkers is that

  2024-01-18

  

  An issue related to research without biomarkers is that many studies will ascertain some but not all biomarker groups in study participants. Because tau PET is relatively new, incomplete biomarker information will occur in studies that use imaging for amyloid and neurodegenerative biomarker characte

• Alectinib is a second generation ALK antagonist

  2024-01-18

  

  Alectinib is a second generation ALK antagonist that is built upon a 9-ethyl-6, 6-dimethyl-11-oxo benzo[b]carbazole scaffold (Fig. 5C) [58]. This drug is effective against the ALK L1196M gatekeeper mutation along with C1156Y and F1174L mutations [7]. The 11-oxo group of the drug forms a β-Tocotrieno

• Heat shock protein Hsp is

  2024-01-18

  

  Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a central role in regulating the maturation, activation and stability of numerous “client proteins” that drive the development and progression of many cancers. Therefore, inhibition of Hsp90 would result in degradation of the client p

• To this the evidence of opposite effects of

  2024-01-18

  

  To this, the evidence of opposite effects of noradrenaline and adrenaline on the striatal firing initiation (Fig. 6, Fig. 7) should not be ignored, because the striatum is related to controlling action timing by regulating the firing increase rate (Tanaka and Kunimatsu, 2011). Although the ligand su

• Astemizole br Concluding remarks Following the disappointing

  2024-01-18

  

  Concluding remarks Following the disappointing outcomes of Aβ immunotherapy trials for AD [62], the current prevailing concept is that disease-modifying therapy must be initiated from the presymptomatic stage of the disease because of the presumed incurability of chronic diseases once they become

14400 records 152/960 page Previous Next First page 上5页 151152153154155 下5页 Last page